Randomized study of two "rescue" therapies for helicobacter pylori-infected patients after failure of standard triple therapies

Perri, Francesco; Festa, V.; Clemente, R.; Villani, M; Quitadamo, M.; Caruso, N.; Bergoli, Michele Li; Andriulli, Angelo

doi:10.1111/j.1572-0241.2001.03452.x

Cited by 114 publications

(151 citation statements)

References 18 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Rifabutin is an antitubercolotic compound which has been used, reaching interesting eradication rates ranging from 71 to 86.6%. 20,21 However, rifabutin is expensive, associated with mielotoxicity, 22 and, as it is a useful antimicrobial drug for tuberculosis, its widespread use should be limited to prevent developing resistance to it. Furazolidone has also been proposed but it is associated with important adverse events too.…”

Section: Discussionmentioning

confidence: 99%

A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses

Gatta

Zullo

Perna

et al. 2005

Aliment Pharmacol Ther

109

View full text Add to dashboard Cite

Background: A standard third-line treatment is lacking, and European guidelines recommend performing culture in these patients. However, the use of this procedure as 'routine practice' is definitively not feasible. Aim: To evaluate the eradication rate of a 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses for Helicobacter pylori. Methods: A total of 151 patients with persistent Helicobacter pylori infection after two treatments were studied. Patients were considered positive if two of three endoscopic tests were positive. Susceptibility testing was also performed. Patients received a standard dose of

show abstract

Section: Discussionmentioning

confidence: 99%

A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses

Gatta

Zullo

Perna

et al. 2005

Aliment Pharmacol Ther

109

View full text Add to dashboard Cite

show abstract

“…Furthermore, rifabutin-based therapies have been compared with the widely used 'classic' quadruple therapy. Perri et al [2001a] performed a randomized study where three groups of patients were treated for 10 days with pantoprazole, amoxicillin and rifabutin 150 mg once daily, or 300 mg once daily, and quadruple therapy. On intention-to-treat analysis, eradication rates were 67% in the rifabutin 150 mg and quadruple groups, and higher (87%) in the rifabutin 300 mg group.…”

Section: Amoxicillin±tetracycline-based Regimensmentioning

confidence: 99%

Review: Second-line rescue therapy of Helicobacter pylori infection

Gisbert

2009

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Helicobacter pylori infection is the main known cause of gastritis, gastroduodenal ulcer disease and gastric cancer. After more than 20 years of experience in H. pylori treatment, however, the ideal regimen to treat this infection has still to be found. Nowadays, apart from having to know well first-line eradication regimens, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a 'rescue' treatment depends on which treatment is used initially. If a first-line clarithromycin-based regimen was used, a second-line metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third-line 'rescue' option. Alternatively, it has recently been suggested that levofloxacin-based 'rescue' therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, quadruple regimen may be reserved as a third-line 'rescue' option. Finally, rifabutin-based 'rescue' therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H. pylori eradication can finally be achieved in almost all patients if several 'rescue' therapies are consecutively given. Therefore, the attitude in H. pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

show abstract

“…The rifamycin rifabutin has been reported to be an effective component of multiple drug therapy for the treatment of recalcitrant cases of peptic ulcer disease that were failures of first-line therapies [7,8]. Rifalazil (RFZ), also known as KRM-1648 or ABI-1648 [8], has been shown to have very potent in vitro activity against H. Each compound, ABI-0089, ABI-0094, ABI-0369, ABI-0418, and RFZ, were dosed at 4.0 mg/kg BID PO for 7 days to 3 mice, stomachs were harvested and homogenized 12 hours after the last dose, and the titer was compared to mice administered vehicle only (designated "V only").…”

Section: Introductionmentioning

confidence: 99%

“…Rifalazil (RFZ), also known as KRM-1648 or ABI-1648 [8], has been shown to have very potent in vitro activity against H. Each compound, ABI-0089, ABI-0094, ABI-0369, ABI-0418, and RFZ, were dosed at 4.0 mg/kg BID PO for 7 days to 3 mice, stomachs were harvested and homogenized 12 hours after the last dose, and the titer was compared to mice administered vehicle only (designated "V only"). Standard error is indicated by error bars.…”

Section: Introductionmentioning

confidence: 99%

Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization

Rothstein

Mullin

Sirokman³

et al. 2008

J Antibiot

View full text Add to dashboard Cite

show abstract

Randomized study of two "rescue" therapies for helicobacter pylori-infected patients after failure of standard triple therapies

Abstract: In patients who failed standard eradicating treatments, a 10-day course of rifabutin with pantoprazole and amoxycillin is more effective and well tolerated than the quadruple therapy.

Cited by 114 publications

References 18 publications

A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses

A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses

Review: Second-line rescue therapy of Helicobacter pylori infection

Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization

Contact Info

Product

Resources

About